I have seen many therioes as to what may happen I guess i'll throw mine out there. There is a company out there called xenomics symbol xnom. This may be our merger or partnership just. IMHO if you notice what company he co-founded.
Thomas H. Adams, a Leading Diagnostic Entrepreneur, Named Chairman of Xenomics, Inc.Font size: A | A | A6:56 PM ET 4/16/09 | BusinessWire
RELATED QUOTES
4:00 PM ET 5/11/09
Symbol Last % Chg
GNTA 0.02 20.29%
XNOM 0.39 0.00%
Quotes delayed at least 15 minutes
Xenomics Inc. (XNOM.PK), a developer of non-invasive next-generation molecular diagnostics, announced today the appointment of renowned medical diagnostic entrepreneur Thomas H. Adams, Ph.D. as Chairman of the Board of Xenomics Inc by written consent of the holders of a majority of the outstanding shares. Dr. Adams is the co-founder of a number of successful diagnostic and pharmaceutical companies including Genprobe Inc, Hybritech Inc., Genta Inc. and Leucadia Technologies, Inc. Today Genprobe Inc is the world leader in diagnostics to detect and monitor sexually transmitted diseases, with a market cap of approximately $2.5 billion dollars. Hybritech Inc. was the developer of the PSA test, the most widely used diagnostic test for adult males, to measure risk of prostate cancer. Dr. Adams is a senior executive of Iris Inc. which acquired Leucadia Technologies.
"Xenomics trans-renal DNA disease detection diagnostic platform offers significant advantages over conventional tests," said Dr. Adams. "The company is using this platform to create truly revolutionary diagnostic applications that are only achievable using Xenomics' patented trans-renal technology," he continued.
The company looks forward to strategically refocusing its development and partnering efforts, with Dr. Adams' experienced guidance, as well as building a world class development team.
About Xenomics
Xenomics is a molecular diagnostics company developing tests based on Transrenal nucleic acids (Tr-DNA and Tr-RNA) and safe, simple urine collection techniques. The Company believes its proprietary technologyhas a broad range of detection / monitoring / screening applications,including for prenatal conditions, infectious diseases, tissue transplantation, neurodegenerative disorders, various tumors, and can open significant new markets in the molecular diagnostics field. Xenomics has a strong and broad IP portfolio of issued and pending patents covering different applications of the technology for molecular diagnostics.
Never underestimate the power of very stupid people in large groups.
